

through the use of automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

ADDRESSES: To request additional information, please contact Lisa Neel by one of the following methods:

- *Mail:* Lisa Neel, Program Manager, HIV Program, Office of Clinical and Preventive Services, Indian Health Service, 5600 Fishers Lane, Mail Stop: 08N06–A, Rockville, MD 20857.

- *Phone:* 301–443–4305.
- *Email:* Lisa.Neel@ihs.gov.
- *Fax:* 301–443–4305.

Direct Your Comments to OMB: Send your comments and suggestions regarding the proposed information collection contained in this notice, especially regarding the estimated public burden and associated response time to: Office of Management and Budget, Office of Regulatory Affairs, New Executive Office Building, Room 10235, Washington, DC 20503, Attention: Desk Officer for IHS.

Comment Due Date: Your comments regarding this information collection is best assured of having full effect if received within 30 days of the date of this publication.

Dated: June 29, 2016.

Elizabeth A. Fowler,

Deputy Director for Management Operations, Indian Health Service.

[FR Doc. 2016–16207 Filed 7–8–16; 8:45 am]

BILLING CODE 4165–16–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Notice of Meeting

AGENCY: Center for Substance Abuse Prevention, Substance Abuse and Mental Health Services Administration, HHS.

Pursuant to Public Law 92–463, notice is hereby given that the Substance Abuse and Mental Health Services Administration’s (SAMHSA) Center for Substance Abuse Prevention (CSAP) Drug Testing Advisory Board (DTAB) will meet on July 26 and July 27, 2016. The DTAB will convene in both open and closed sessions over these two days.

On July 26, 2016 from 9:00 a.m. to 5:00 p.m. EDT, the meeting will be open to the public to provide an update on the status of the Mandatory Guidelines for Federal Workplace Drug Testing

Programs for urine and oral fluid. A description of technical issues associated with hair testing will also be provided.

The public is invited to attend the open session in person or to listen via web conference. Due to the limited seating space and call-in capacity, registration is requested. Public comments are welcome. To register, make arrangements to attend, obtain the teleconference call-in numbers and access codes, submit written or brief oral comments, or request special accommodations for persons with disabilities, please register at the SAMHSA Advisory Committees’ Web site at <http://nac.samhsa.gov/Registration/meetingsRegistration.aspx> or contact the CSAP DTAB Designated Federal Official, Brian Makela (see contact information below).

On July 27, 2016 between 9:00 a.m. and 2:00 p.m. E.D.T., the Board will meet in closed session to discuss proposed revisions to the Mandatory Guidelines for Federal Workplace Drug Testing Programs. This portion of the meeting is closed to the public as determined by the Administrator, SAMHSA, in accordance with 5 U.S.C. 552b(c)(9)(B) and 5 U.S.C. App. 2, Section 10(d).

Substantive program information, a summary of the meeting, and a roster of DTAB members may be obtained as soon as possible after the meeting by accessing the SAMHSA Advisory Committees Web site, <http://www.nace.samhsa.gov/MeetingList.aspx>, or by contacting Brian Makela. The transcript for the open meeting will also be available on the SAMHSA Committee Web site within three weeks after the meeting.

Committee Name: Substance Abuse and Mental Health Services Administration’s Center for Substance Abuse Prevention, Drug Testing Advisory Board.

Dates/Time/Type: July 26, 2016 from 9:00 a.m. to 5:00 p.m. E.D.T.: OPEN; July 27, 2016 from 9:00 a.m. to 2:00 p.m. E.D.T.: CLOSED.

Place: 7500 Old Georgetown Rd., Bethesda, Maryland 20814.

Contact: Brian Makela, Designated Federal Official, CSAP Drug Testing Advisory Board, 5600 Fishers Lane, Room 16N02B, Rockville, Maryland 20857, *Telephone:* 240–276–2600, *Email:* brian.makela@samhsa.hhs.gov.

Summer King,

Statistician.

[FR Doc. 2016–16358 Filed 7–8–16; 8:45 am]

BILLING CODE 4162–20–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Agency Information Collection Activities: Proposed Collection; Comment Request

In compliance with section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 concerning opportunity for public comment on proposed collections of information, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the information collection plans, call the SAMHSA Reports Clearance Officer on (240) 276–1243.

Comments are invited on: (a) Whether the proposed collections of information are necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Proposed Project: Confidentiality of Alcohol and Drug Abuse Patient Records—(OMB No. 0930–0092)—Revision

Statute (42 U.S.C. 290dd–2) and regulations (42 CFR part 2) require federally conducted, regulated, or directly or indirectly assisted alcohol and drug abuse programs to keep alcohol and drug abuse patient records confidential. Information requirements are (1) written disclosure to patients about Federal laws and regulations that protect the confidentiality of each patient, and (2) documenting “medical personnel” status of recipients of a disclosure to meet a medical emergency. Annual burden estimates for these requirements are summarized in the table below: